⁴⁴Sc-PSMA-617 for radiotheragnostics in tandem with ¹⁷⁷Lu-PSMA-617—preclinical investigations in comparison with ⁶⁸Ga-PSMA-11 and ⁶⁸Ga-PSMA-617

详细信息    查看全文

• 作者：Christoph A. Umbricht ; Martina Benešová ; Raffaella M. Schmid…
• 关键词：44Sc ; 68Ga ; 177Lu ; Prostate cancer ; PSMA ; PET imaging ; Theragnostics ; Cyclotron
• 刊名：EJNMMI Research
• 出版年：2017
• 出版时间：December 2017
• 年：2017
• 卷：7
• 期：1
• 全文大小：1929KB
• 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：2191-219X
• 卷排序：7

文摘

BackgroundThe targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic purposes of prostate cancer. Radiolabeled PSMA-617, a 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA)-functionalized PSMA ligand, revealed favorable kinetics with high tumor uptake, enabling its successful application for PET imaging (68Ga) and radionuclide therapy (177Lu) in the clinics. In this study, PSMA-617 was labeled with cyclotron-produced 44Sc (T_1/2 = 4.04 h) and investigated preclinically for its use as a diagnostic match to 177Lu-PSMA-617.